Enochian Biosciences Inc

Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Enochian Biosciences Inc (NASDAQ: ENOB) shares are trading lower Wednesday after Hindenburg Research issued a bearish report on the company. Last week, federal prosecutors announced the arrest of two men being charged in a "murder-for-hire" conspiracy, which resulted in the.

'Murder-For-Hire Conspiracy': Why Enochian Biosciences Stock Is Plunging

Shares of ENOB stock are down over 30% after Hindenburg Research released a short report detailing co-founder Gumrukcu's spotty past. The post Enochian (ENOB) Stock Falls 30% on ‘Murder for Hire' Short Report appeared first on InvestorPlace.

Enochian (ENOB) Stock Falls 30% on ‘Murder for Hire' Short Report

LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences is working to solve our greatest public health threats like HIV, cancer, and coronavirus. The company's underlying scientific ideas are innovative with an elegant simplicity, characteristics that are often a hallmark of groundbreaking advances. The company is working to push through systems and barriers to translate these innovative ideas into potential products that could save lives.

Scientific Leaders Agree on Promise of Enochian BioSciences

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Enochian Biosciences, Inc. (“Enochian” or the “Company”) (NASDAQ: ENOB) on behalf of Enochian stockholders. Our investigation concerns whether Enochian has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 25, 2022, the United State Attorney's Office for t

ENOCHIAN ALERT: Bragar Eagel & Squire, P.C. is Investigating Enochian Biosciences, Inc. on Behalf of Enochian Stockholders and Encourages Investors to Contact the Firm

Enochian Bioscience is in the green today following the shocking arrest of the company founder earlier this week. ENOB stock closed up 20%.

ENOB Stock Gains 20% Following Founder Arrest, Hindenburg Short

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Enochian Biosciences, Inc. (NASDAQ: ENOB) resulting from allegations that Enochian BioSciences may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Enochian BioSciences securities you may be entitled to compensation without payment of any out of pocket fees or costs throu

EQUITY ALERT: Rosen Law Firm Encourages Enochian Biosciences, Inc. Investors with Losses to Inquire About Class Action Investigation – ENOB

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Enochian Biosciences, Inc. (“Enochian” or the “Company”) (NASDAQ: ENOB) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Enochian investments or would like to inquire about potentially pursuing claims to recover your loss under the federal sec

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Enochian Biosciences, Inc. (ENOB) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Enochian Biosciences, Inc. (“Enochian” or the “Company”) (NASDAQ: ENOB) investors concerning the Company's possible violations of federal securities laws. On May 25, 2022, the U.S. Department of Justice announced that Serhat Gumrukcu, the inventor and co-founder of Enochian, had been arrested and charged in a murder-for-hire conspiracy. On this news, Enochian's stock fell $2.17, or 37%, to clo

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Enochian Biosciences, Inc. (ENOB) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Enochian Biosciences, Inc. (“Enochian” or the “Company”) (NASDAQ: ENOB) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 25, 2022, the U.S. Department of Justice announced that Serhat Gumrukcu, the inventor and co-founder of Enochian, had been arrested and charged in a murder-fo

The Law Offices of Frank R. Cruz Announces Investigation of Enochian Biosciences, Inc. (ENOB) on Behalf of Investors

BlackSky Technology

Kohl's

Maxar Technologies

Verrica Pharmaceuticals Inc

Valvoline

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore and bring order to the markets.

6 Stocks Halted In Wednesday's Session: Here's Why

LOS ANGELES, May 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). The Board of Directors of Enochian BioSciences Inc. met today and expressed unanimous and strong affirmation of the current position of the Company, the Management and the promising advancement of the Research and Development pipeline.

Enochian BioSciences Board Learns of Arrest of Co-Founder and Inventor and Expresses Strong Confidence in the Promising Future of the Company

LOS ANGELES, April 20, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences (NASDAQ: ENOB). Enochian BioSciences Inc., a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, today is announcing the appointment of Dr. François Binette, Ph.D. as Executive Vice President for Research and Development. Dr. Binette brings over 25 years of Advanced Therapy and Regenerative Medicine product development expertise, most recently as Senior VP of Product Development at Lineage Cell Therapeutics where he led multiple innovative allogenic cell therapy programs from discovery to clinical stages and contributed to one of the largest non-cancer cell therapy corporate partnership deals with Genentech worth over $650 million in upfront and milestone payments. He previously held positions at Johnson and Johnson, where he led several innovative regenerative medicine combination product development initiatives from discovery to approved clinical trials in the US and Europe, and at Medtronics, developing biologics, active devices, and combination products.

Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience

LOS ANGELES, April 07, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., (NASDAQ: ENOB), a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, announced today that Greg Duczynski is joining as Senior Vice President for Clinical Operations after a distinguished 32-year career with Pfizer. Since 2016, he has served as Senior Director, Clinical Development and Operations and Clinical Study Team Leader. He has been leading an international trial of gene therapy.

Enochian BioSciences Announces Appointment of Senior Vice President for Clinical Operations with 32 Years' Experience at Pfizer

LOS ANGELES, April 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced that Dr. Serhat Gumrukçu, the inventor and co-founder of the Company, delivered the concluding Plenary Lecture at the Innate Killer Summit in San Diego, California as an invited speaker (Link to Presentation.)

Enochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer Summit

LOS ANGELES, March 15, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, has issued an exclusive sub-license of one of its proprietary technologies that could improve the effectiveness of a potential cure for HIV with an anti-HIV CAR-T therapy that Caring Cross is studying in a clinical trial. Caring Cross is an innovative non-profit that partners with others, including for-profit companies, to increase access to new technologies and medicines under a collaborative value sharing model. Caring Cross and Enochian BioSciences entered into a profit-sharing agreement as part of the sub-license.

Enochian BioSciences and Caring Cross Announce a Partnership to Potentially Increase the Effectiveness of a CAR-T Approach for HIV Cure Currently Being Studied in Humans

LOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, Inventor and Co-Founder of Enochian BioSciences, and Founder and Director of Seraph Research Institute (SRI), presented new data and announced a partnership between Enochian and Dr. Anahid Jewett, a leader in tumor immunology and cell and gene therapy, on pancreatic cancer, as well as a combined effort with SRI and Enochian on Glioblastoma.

Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid Tumors

The stock price of Enochian Biosciences Inc (NASDAQ: ENOB) increased by over 3% pre-market today. This is why it happened.

ENOB Stock: Why The Price Increased Today

Company encouraged by clear path to IND in near-term following its review of the FDA's Center for Biologics Evaluation and Research written comments Company encouraged by clear path to IND in near-term following its review of the FDA's Center for Biologics Evaluation and Research written comments

Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month

LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that Dr. Peter Piot has resigned as Chairperson of the Respiratory Diseases Scientific Advisory Board due to important responsibilities advising a major governmental organization on COVID-19 that creates a conflict.

Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity

LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference.

Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

Company encouraged by clear path following review of FDA's CBER written comments Company encouraged by clear path following review of FDA's CBER written comments

Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection

LOS ANGELES, Aug. 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced the appointment of internationally renowned scientists and public health leaders to a Scientific Advisory Board (SAB) focused on potential inhaled treatment and prevention of any current or future variants of SARS-CoV-2 – the virus that causes COVID-19 – and Influenza.

Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences' Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants

LOS ANGELES, Aug. 23, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that the renowned Dr. Anna Suk-Fong Lok, MD, has joined the Scientific Advisory Board for a potential cure for Hepatitis B Virus (HBV), that causes liver disease in approximately 350 million people globally and 1 million deaths every year.

Distinguished Scientific and Clinical Leader to Join Enochian BioSciences' Hepatitis B Cure Scientific Advisory Board

Dr. Dybul's Deep and Prestigious Scientific Research Expertise Helps to Affirm Enochian BioSciences' Scientific Approach Dr. Dybul's Deep and Prestigious Scientific Research Expertise Helps to Affirm Enochian BioSciences' Scientific Approach

Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer

Enochian BioSciences Inc (NASDAQ: ENOB) has announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall.

News for Enochian Biosciences Inc Stock (ENOB)